Program
BPL-003
A development code.
Its studies are mostly in Depressive Disorder, Treatment-Resistant · Alcoholism, led by Eli Lilly.
Furthest: phase 2, since Dec 13, 20224 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 41 open or running | phase 2since Dec 13, 2022 | Apr 21, 2022 | Nov 2026phase 2 · NCT05660642 |
- Named in Eli Lilly’s own pipeline as
Intranasal 5-MeO-DMT
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 21, 2022First study: phase 1 study in Pharmacokinetics in Healthy AdultsFirst studyNCT05347849 · 62 enrolled · United Kingdom
- Dec 13, 20222 phase 2 studiesNCT05674929, NCT05660642
- May 12, 2023Phase 2 study in Depressive Disorder, Treatment-ResistantNCT05870540 · 196 enrolled · United States, Australia, Germany and more
Ahead
- Nov 2026Primary completion: phase 2 study in Depressive Disorder, Treatment-ResistantNCT05660642
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05870540Depressive Disorder, Treatment-Resistant · United States, Australia, Germany and more | 2 | Completed | Mar 28, 2025 | 196 |
| NCT05674929Alcoholism · United Kingdom | 2 | Completed | Oct 2, 2024 | 13 |
| NCT05660642Depressive Disorder, Treatment-Resistant · United Kingdom | 2 | Recruiting | Nov 2026 | 72 |
| NCT05347849Pharmacokinetics in Healthy Adults · United Kingdom | 1 | Completed | Jan 19, 2024 | 62 |
How it is read
Names in the registry
- “BPL-003”, 5 entries
Codes read as this program: BPL003.
Conditions, from the studies’ own filings
- Depressive Disorder, Treatment-Resistant, 2 studies
- Alcoholism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.